Portal vein tumour thrombus (macrovascular invasion)
Liver cancer growing into the main vein that brings blood from the gut to the liver. It marks advanced disease, rules out most surgery and transplant, and makes some local treatments unsafe.
Hepatocellular carcinoma has a propensity to invade the portal and hepatic veins; macrovascular invasion defines BCLC stage C, excludes transplantation and usually resection, and makes TACE hazardous because the liver would lose both blood supplies, so radioembolisation, radiotherapy to the thrombus or systemic therapy (atezolizumab-bevacizumab) are used. Portal hypertension from cirrhosis, separately, causes varices and ascites and limits treatment options. Renal cell carcinoma can similarly extend into the renal vein and inferior vena cava, which is removed with the kidney.
Pages like this
not linked directly; found by shared links- TermTACE (transarterial chemoembolisation)
Shares TARE / SIRT (radioembolisation with yttrium-90), BCLC staging, Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermChild-Pugh score
Shares Cirrhosis, BCLC staging, Hepatocellular carcinoma.
- TermDownstaging and conversion therapy
Shares BCLC staging, Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermChild-Pugh and ALBI liver-function scores
Shares BCLC staging, Hepatocellular carcinoma.
- CompanyBoston Scientific
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TrialEMERALD-1
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TermLiver-directed therapy (TACE, TARE, HAI, ablation)
Shares TARE / SIRT (radioembolisation with yttrium-90), Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TrialLEAP-012
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.